"Seattle CRC has undergone a few transitions in our nearly 3-decade history but has continued to uphold the same great quality care, innovative research, and excellent service. Seattle CRC strives to be on the cutting edge of healthcare research and is always looking to expand our reach within clinical trials. As we continue to grow and expand our areas of focus, our approach to innovative research and creating a standard of excellence of care for all individuals remains the same."

During the past decade, Women's Clinical Research Center conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 37 clinical trials were completed, i.e. on average, 86% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 26 clinical trials were completed. i.e. 144.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Women's Clinical Research Center" #1 sponsor was "Bayer" with 7 trials, followed by "Pfizer" with 6 trials sponsored, "Curatek Pharmaceuticals, LLC" with 3 trials sponsored, "Ferring Pharmaceuticals" with 3 trials sponsored and "GTx" with 3 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Women's Clinical Research Center" #1 collaborator was "Chemo France" with 1 trials as a collaborator, "Chemo Research" with 1 trials as a collaborator, "Daré Bioscience, Inc." with 1 trials as a collaborator, "Health Decisions" with 1 trials as a collaborator and "IQVIA Inc." with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Women's Clinical Research Center" are "Contraception" (9 trials), "Hot Flashes" (6 trials), "Migraine" (5 trials), "Migraine, With or Without Aura" (4 trials) and "Overactive Bladder" (4 trials). Many other conditions were trialed in "Women's Clinical Research Center" in a lesser frequency.

Most popular intervention types in "Women's Clinical Research Center" are "Drug" (68 trials), "Biological" (4 trials), "Other" (2 trials), "Combination Product" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (27 trials), "Brisdelle (paroxetine mesylate)" (3 trials), "Rimegepant" (3 trials), "Vehicle" (3 trials) and "Elinzanetant (BAY3427080)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Women's Clinical Research Center" are 49 trials for "Female" genders and 23 trials for "All" genders.

Currently, there are NaN active trials in "Women's Clinical Research Center". 1 are not yet recruiting, 9 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 51 completed trials in Women's Clinical Research Center, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Women's Clinical Research Center, 1 "Phase 1" clinical trials were conducted, 28 "Phase 2" clinical trials and 39 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".